CME vs IBN

CME Group trades near fair value with strong profitability and a dominant market position in financial derivatives, supported by a 58.95% profit margin and 63.39% operating margin—both well above sector averages. However, near-term revenue contraction (-3.0% YoY) and stagnant earnings growth (0.0% YoY) raise concerns about cyclical headwinds, while the P/E of 27.6x is above the sector average of 21.8x, limiting upside. Price momentum remains solid with a 1Y return of +33.3%, but insider selling and a 103.7% payout ratio signal caution. Analysts are unanimous in a 'hold' rating, aligning with our neutral stance given mixed fundamentals and valuation.

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating deteriorating operational trends. However, the valuation remains attractive with a PEG ratio of 0.52 and a current price ($27.54) sitting below the growth-based intrinsic value of $31.16. While revenue growth is explosive at 66.90%, the technical trend is currently bearish (0/100) and the 1-year price performance is negative. The stock presents a conflict between strong growth/valuation metrics and poor short-term financial health and price momentum.